A new Scottish research is suggesting that aspirin does not prevent heart attacks in people with diabetes.
The British Medical Journal reported that aspirin should only be given to patients with established heart disease, stroke or limb arterial disease.
Heart Attack
Heart attack is the death of the heart muscle due to loss of blood supply. Heart disease is the leading cause of death in the United States. Other names for heart attack include acute myocardial infarction, coronary thrombosis, and coronary occlusion.
Advertisement
The study found that in nearly 1,300 adults with no symptoms of heart disease the drug, which can cause stomach bleeds, had no benefit.
The findings contradict many guidelines, which advocate people with diabetes use aspirin to counter the underlying high risk of heart attack and stroke.
![Chest Pain]( "Chest Pain")
Ask any one who has experienced intense chest pain and they will vouch for the fact that it was the most frightening experience of their life!
But there are key high-risk groups who still need the drug, experts said.
Patients with diabetes are two to five times more likely to suffer from heart disease than the general population and heart disease is a major cause of death in patients with type 1 and 2 diabetes.
To reach the conclusion, professor Jill Belch and colleagues from Scotland investigated whether aspirin and antioxidants given together or separately can reduce heart attacks and death in patients with diabetes and arterial disease. 1276 patients with diabetes and evidence of artery disease over 40 years of age were randomised to receive either aspirin or placebo, an antioxidant or placebo, aspirin and antioxidant or double placebo, and followed over eight years.
Overall, the researchers found no benefit from either aspirin or antioxidant treatment in the prevention of heart attacks or death. Patients in the aspirin groups had 116 primary events compared with 117 in the placebo group. No significant difference in events was seen between the antioxidant group and the placebo group.
The study has been published in the British Medical Journal.
Source: ANI
RAS/SK
Chest Pain
Ask any one who has experienced intense chest pain and they will vouch for the fact that it was the most frightening experience of their life!
Advertisement
But there are key high-risk groups who still need the drug, experts said.
Patients with diabetes are two to five times more likely to suffer from heart disease than the general population and heart disease is a major cause of death in patients with type 1 and 2 diabetes.
To reach the conclusion, professor Jill Belch and colleagues from Scotland investigated whether aspirin and antioxidants given together or separately can reduce heart attacks and death in patients with diabetes and arterial disease. 1276 patients with diabetes and evidence of artery disease over 40 years of age were randomised to receive either aspirin or placebo, an antioxidant or placebo, aspirin and antioxidant or double placebo, and followed over eight years.
Overall, the researchers found no benefit from either aspirin or antioxidant treatment in the prevention of heart attacks or death. Patients in the aspirin groups had 116 primary events compared with 117 in the placebo group. No significant difference in events was seen between the antioxidant group and the placebo group.
The study has been published in the British Medical Journal.
Source: ANI
RAS/SK
Cholesterol
Cholesterol is produced by the body (liver) and is essential for normal body functioning.
Advertisement
 Animation of heart attack symptoms - AnimationHeart attack can cause symptoms such as Chest pain or discomfort, Shortness of breath and pain in neck, back, arm, or shoulder and is due to blockage of blood supply to the heart muscles | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.